Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer

Executive Summary

Will submit two NDAs over the next 12 months, including the oral antibiotic Unasyn (sultamicillin) and an azolide antibiotic azithromycin, firm reported at April 27 annual meeting. An injectable form of Unasyn (sulbactam/ampicillin) was approved for U.S. marketing in December 1987. Pfizer currently has eight NDAs pending at FDA, the company said. Among drugs pending agency approval are the antifungal Diflucan (fluconazole), filed March 1, Xomen-E5, Xoma's monoclonal antibody-based treatment for gram negative sepsis developed in conjunction with Pfizer, Procardia XL, Minipress XL, the vasodilator Cardura (see related story), Norvasc, the anti-depressant sertraline, and the selective antihistamine cetirizine.

You may also be interested in...



COVID-19: FDA Schedules 4 More Virtual Town Halls Through February

The US agency has announced another month of webinars aimed at labs and manufacturers that are (or have) developed diagnostic tests for the novel coronavirus.

GSK Ends Tough Week With Ulcerative Colitis Therapy Termination

If bad luck comes in threes, GSK will be delighted to see the end of this week with dostarlimab approval delayed, bintrafusp failing in lung cancer and a Phase II of an ulcerative colitis drug discontinued.

Global Pharma Industry Regulators Seek Unified Approach To Remote Inspections

Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel